Glaucoma

Published on 02/03/2015 by admin

Filed under Basic Science

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 1 (2 votes)

This article have been viewed 3541 times

55 Glaucoma

The term ‘glaucoma’ does not represent a single pathological entity. It consists of a large group of disorders with widely differing clinical features. It is, therefore, difficult to attempt a single definition of the term. High intraocular pressure (IOP) was previously used as a diagnostic criterion for glaucoma, but more recently, it has been recognised purely as the most important risk factor for the disease. This is because glaucoma can occur even in patients with normal IOP (normal-pressure chronic open-angle glaucoma, COAG). The ‘normal’ IOP (10–21 mmHg) is a statistical description of the range of IOP in the population and is not applicable to an individual subject. It is thought to increase with age, at the rate of approximately 1 mmHg every decade after the age of 40 years in the Western population. There is a circadian cycle of IOP, with maximum levels often occurring between 8 and 11 a.m. and minimum levels between midnight and 2 a.m. This may affect IOP readings taken in outpatient clinics at different times of the day. The normal diurnal variation is between 3 and 5 mmHg, and this is wider in untreated glaucoma. Although a raised IOP is not the only cause of glaucoma, it is the only parameter that can currently be changed by pharmacological intervention and therefore plays an important part in the evaluation of disease progression.

Current thinking is that once the rate of disease progression has been established, a ‘target IOP’ can be set. The target IOP is defined as a dynamic, clinical judgement about what level of IOP is considered by the healthcare professional treating the patient to be sufficiently low to minimise or arrest disease progression or onset and avoid disability from sight loss within a person’s expected lifetime.

It is, however, extremely difficult to accurately assess in advance the IOP level at which further damage will occur for any one patient. As the correct target IOP is only discovered with hindsight, one limitation is that the chosen target IOP may not be low enough and a patient must get worse before it is realised that the target IOP was inadequate. There is no single safe IOP level for all patients, but in general, the aim is to achieve at least a 25–30% reduction from the initial IOP at which damage occurred. In advanced disease, the aim is to achieve an IOP level below 18 mmHg at all times. This can be used as a good method to set an initial target IOP. However, it is essential that the patient receives regular periodic re-evaluation so that the target IOP can be adjusted according to disease progression and treatment adjusted accordingly.

Epidemiology

The World Health Organisation has estimated that globally there are 12.5 million people blind from glaucoma with the total number affected by this condition at around 66 million. Approximately 13% of UK blindness registrations are ascribed to glaucoma, and around 2% of people older than 40 years have COAG, a figure which rises to almost 10% in people older than 75 years. With changes in population demographics, the number of individuals affected by glaucoma is expected to rise. Based on these estimates, there are around 500,000 people affected by COAG in England and Wales, who receive over a million glaucoma-related outpatient visits in the hospital eye service annually. Once diagnosed, affected individuals require lifelong monitoring for disease control and to detect possible progression of visual damage. Once lost, vision cannot be restored. Disease control with prevention or at least minimisation of ongoing damage is therefore paramount to maintain sight.

The diseases which make up the group known as glaucoma are usually classified according to the manner in which aqueous humour outflow is impaired.

Pathophysiology

The primary site of damage is thought to be the optic nerve head, rather than any other point along the nerve axon. This most easily explains the progressive loss of visual field. Studies of axoplasmic flow show a vulnerability of the nerves to elevated IOP as they pass through the optic disc.

In COAG, increased resistance within the drainage channels causes the rise in IOP. It is thought that the main route of resistance to aqueous outflow lies in the dense juxtacanalicular trabecular meshwork, or the endothelium lining the inner wall of Schlemm’s canal.

In PACG, the rise in IOP is caused by a decreased outflow of aqueous humour, due to closure of the chamber angle by the peripheral iris. It occurs in predisposed eyes, and the predisposing factors can be anatomical or physiological. The anatomical characteristics are lens size, corneal diameter and axial length of the globe. The lens continues to grow throughout life. This brings the anterior surface closer to the cornea. Slackening of the suspensory ligaments increases this movement. Both factors occur very gradually and lead to a progressive shallowing of the anterior chamber. The depth of the anterior chamber and width of the chamber angle are related to corneal diameter, and those eyes predisposed to PACG are observed to have a corneal diameter less than that seen in normal eyes. A short eye, which is frequently also hypermetropic, has a small corneal diameter and a thick and relatively anteriorly located lens.

The physiological precipitating factors of PACG in predisposed eyes are not fully understood. Two theories currently exist. The dilator muscle theory suggests that contraction of the dilator muscle causes a posterior movement, which increases the apposition between the iris and anteriorly located lens and the degree of physiological pupillary block. The simultaneous dilation of the pupil renders the peripheral iris more flaccid, and causes the pressure in the posterior chamber to increase and the iris to bow anteriorly. Eventually, the peripheral iris obstructs the angle and the IOP rises (Fig. 55.1).

The sphincter muscle theory postulates that the sphincter of the pupil precipitates angle closure. The pupillary blocking force of the sphincter is greatest when the diameter of the pupil is about 4 mm.

Clinical manifestations

COAG is typically characterised by the following: an IOP greater than 21 mmHg, an open-angle, glaucomatous cupping and visual field loss. COAG, because of its insidious onset, is usually asymptomatic until it has caused a significant loss of visual field. In some eyes, subtle signs of glaucomatous retinal nerve damage can be detected prior to development of pathological cupping and detectable field loss. The earliest clinically significant field defect is a scotoma, which is an area of depressed vision within the visual field. Patients with COAG frequently show a wider swing in IOP than normal; therefore, a single pressure reading of 21 mmHg or less does not exclude the diagnosis. It may be necessary to measure IOP at different times of the day, or at periodic intervals.

Acute PACG is due to a sudden closure of the angle and a severe elevation in IOP. The symptoms include rapidly progressive visual impairment, periocular pain and congestion of the eye. In severe cases, nausea and vomiting may occur. The signs include injection of the limbal and conjunctival vessels, giving a ‘ciliary flush’. The IOP usually lies between 50 and 80 mmHg and causes corneal oedema with epithelial vesicles. The anterior chamber is shallow and iridocorneal contact can be observed. The pupil is vertically oval and fixed in a semidilated position. It is unreactive to light and accommodation. The fellow eye usually has a shallow anterior chamber and a narrow angle. The optic nerve head is oedematous and hyperaemic.

Investigations

IOP may be measured by tonometry, such as indentation tonometry in which a plunger is applied to the cornea and the amount of indentation on the eye reflects the pressure within it. Tonography is a technique used to measure the outflow of aqueous humour from the eye, resulting from indentation of the eye, using a tonometer. Gonioscopy is used to estimate the width of the chamber angle, with the aid of a slit lamp. Perimetry is important for both the diagnosis and management of glaucoma by detecting early scotomata and larger changes in visual field. Other investigations which should be routinely offered to patients include a central corneal thickness measurement (CCT), as this has an effect on the measured IOP and may affect the efficacy of certain drug treatments (Johnson et al., 2008), and fundus examination for optic nerve assessment with dilatation using stereoscopic slit-lamp biomicroscopy. There are also guidelines for the monitoring of these patients and at what intervals their IOP, optic nerve head and visual fields should be checked (National Institute for Health and Clinical Excellence, 2009).

In patients with COAG, cupping of the optic disc becomes progressively apparent and is used in both diagnosis and assessment of the efficacy of treatment. The increased IOP appears to push the optic disc back into an excavation. This is known as glaucomatous cupping.

The colour of the optic disc will be observed to change from a creamy pink colour, due to the rich capillary network seen in the healthy eye, to increased pallor with advancing disease as the optic nerve tissue progressively atrophies.

Treatment

Chronic open-angle glaucomas

The aim of treatment in COAG is to reduce the raised IOP to the target value, preventing further damage to the nerve fibres and the development of further visual field defects to maintain the patient’s visual function and quality of life. The key to effective treatment is careful and regular follow-up, including measurement of visual acuity, tonometry, gonioscopy, evaluation of the optic disc, CCT and perimetry, which is of primary importance.

The actual safe level of IOP is unknown, the importance of disc and field assessment being underlined by evidence that IOP does not rise above the ‘normal’ range in up to 50% of glaucomas (normal-pressure glaucomas). However, in many cases, maximal retardation of the disease process is achieved if the IOP is maintained in the lower teens. The effect on the visual field and the appearance of the optic disc are the only indications that IOP is being controlled at a safe level. A raised IOP without field or disc changes may not require treatment but will need regular review.

The initial treatment of COAG is usually medical. Topical administration is the preferred type of therapy, and there is a wide range of preparations available (Table 55.1). The chosen drug should be administered at its lowest concentration and as infrequently as possible to obtain the desired effect over the whole 24-h period as a high level of diurnal variation in IOP has been shown to be a more important factor in visual field development than the average IOP. A drug with few potential side effects should be chosen, with oral therapy retained as the final option. The prostaglandin analogues latanoprost and travoprost and the prostamide bimatoprost are indicated for first-line use, as are the β-blockers as these produce the greatest fall in IOP (Table 55.2). Carbonic anhydrase inhibitors and sympathomimetics, which result in a smaller fall in IOP, are reserved for patients unresponsive to first-line drugs, in patients in whom the first-line agents are contraindicated or as adjunctive therapy.

Table 55.1 Drugs used in the treatment of chronic open-angle glaucoma

Therapeutic category Primary mechanism
Topical prostaglandins Increase aqueous outflow
Topical prostamides Increase aqueous outflow
Topical β-blocking agents Decrease aqueous formation
Topical miotics Increase aqueous outflow
Topical adrenergic agonists Increase aqueous outflow and decrease aqueous formation
Topical carbonic anhydrase inhibitors Decrease aqueous formation
Oral carbonic anhydrase inhibitors Decrease aqueous formation

Table 55.2 Comparison of reduction in intraocular pressure (IOP) with a range of ocular hypotensive drugs (adapted from van der Valk et al., 2009)

Drug Relative IOP change from baseline at trough (%) (95% CI) Relative IOP change from baseline at peak (%) (95% CI)
Bimatoprost −28 (−29 to −27) −33 (−35 to −31)
Travoprost −29 (−32 to −25) −31 (−32 to −29)
Latanoprost −28 (−30 to −26) −31 (−33 to −29)
Timolol −26 (−28 to −25) −27 (−29 to −25)
Betaxolol −20 (−23 to −17) −23 (−25 to −22)
Dorzolamide −17 (−19 to −15) −22 (−24 to −20)
Brinzolamide −17 (−19 to −15) −17 (−19 to −15)
Brimonidine −18 (−21 to −14) −25 (−28 to −22)
Placebo −5 (−9 to −1) −5 (−10 to 0)

In most cases, the initial topical treatment is with a prostaglandin analogue or prostamide. If this is ineffective, another prostaglandin or prostamide may be substituted or a β-blocker used instead. Patients not reaching their target pressure on one first-line agent may be prescribed another concomitantly. Alternatively, a carbonic anhydrase inhibitor or a sympathomimetic may be added to one of the first-line drugs. Guidance on the treatment of people with OHT or suspected COAG has been published (National Institute for Health and Clinical Excellence, 2009). The treatment options (Table 55.3) take into account central corneal thickness and age, although age thresholds are only appropriate where vision is normal (OHT with or without suspected COAG) and the treatment is purely preventative. Pilocarpine is no longer recommended by NICE but is recommended as a second-line agent in European guidelines (European Glaucoma Society, 2008). Oral therapy with carbonic anhydrase inhibitors is usually reserved for use as the final stage of treatment in those complex glaucomas awaiting surgery (Fig. 55.2).

It has been proposed that the improved control of IOP with newer therapies has led to a reduction in surgery for glaucoma (Kenigsberg, 2007). However, some patients still require surgical intervention to reach their target pressure.

The most frequently performed surgical procedures create a fistula to act as a new route for aqueous outflow and the most frequently performed surgery of this type, trabeculectomy, appears more effective in controlling IOP than laser trabeculoplasty, in which a series of laser burns is applied to the trabecular meshwork to improve the outflow of aqueous humour. (Rolim de Moura et al., 2007).

Primary angle-closure glaucoma

The medical management of acute PACG is essentially to prepare the eye for surgical treatment. The aim of treatment is to decrease the IOP and associated inflammation. Analgesics and antiemetics are sometimes needed, dependent on symptom severity, to make the patient comfortable. It is usual to treat the unaffected eye prophylactically with miotics (Fig. 55.3).

Paralysis of the iris sphincter usually occurs at an IOP of more than 60 mmHg, due to ischaemia. Therefore, intensive miotic therapy, previously the treatment of choice in many cases of PACG, is usually ineffective and the IOP needs to be lowered by drugs that reduce aqueous humour production rather than by trying to pull the peripheral iris away from the angle with miotics. An intravenous loading dose of mannitol is usually the first drug of choice with intravenous acetazolamide a possible alternative. This is followed by oral treatment, sometimes in combination with corneal indentation, to physically force aqueous humour into the peripheral anterior chamber and artificially open the angle. This should allow the IOP to drop sufficiently to relieve iris ischaemia and allow the sphincter to respond to pilocarpine therapy.

Once the IOP has been reduced medically, the condition is treated surgically, by either surgical peripheral iridectomy or laser iridotomy, to remove an area of the peripheral iris to allow flow of aqueous humour through an alternative pathway (see Fig. 55.1). Filtration surgery is indicated if a large proportion of the angle has been permanently closed by adhesions between the iris and the cornea.

Drug treatment

Ocular prostanoids: prostaglandin analogues and prostamides

The National Institute for Health and Clinical Excellence (2009) guideline does not differentiate between the prostaglandin analogues and the prostamide bimatoprost, but recommends one of this class for the treatment of COAG, certain patients with OHT and certain COAG suspects (see Table 55.4)

The prostaglandin analogues, latanoprost, travoprost and tafluprost, are ester compounds thought to achieve a fall in IOP primarily by increasing the uveoscleral outflow with no significant effect on other parameters of aqueous humour dynamics, while the prostamide bimatoprost is thought to increase outflow through both trabecular and uveoscleral outflow pathways. However, there is still debate about the precise mechanisms of action of this group (Lim et al., 2008; Toris et al., 2008).

All the drugs in this class are licensed for the reduction of elevated IOP in open-angle glaucoma and OHT, and are administered once daily in the evening.

In a meta-analysis, these drugs have been shown to have a greater effect on both peak and trough readings of IOP than timolol, betaxolol, dorzolamide, brinzolamide or brimonidine, producing falls in IOP of 28–29% at trough and 31–33% at peak as shown in Table 55.2 (van der Valk et al., 2009).

Randomised head-to-head evaluations of prostaglandin therapy demonstrate similar efficacy, but differing hyperemia effects with bimatoprost and travoprost causing more hyperaemia than latanoprost (Eyawo et al., 2009; Honrubia et al., 2009). However, these studies were conducted before the introduction of the new formulations of bimatoprost 0.01% and the benzalkonium chloride–free travoprost.

The prostanoids have some interesting local side effects (Table 55.5). Pigmentation of the iris occurs in patients with mixed colour (green-brown or blue-brown) irides after 3–6 months of use and is a result of increased deposition of melanin in the melanocytes. An increase in the length and thickness of the eyelashes and pigmentation of the palpebral skin are also known side effects. Use of these drugs may lead to disruption of the blood–aqueous barrier in patients with aphakia and pseudophakia (no or false lens, respectively) and increase the risk of developing cystoid macular oedema; they should be used with caution in such patients. Reactivation of herpes simplex infection has been reported with bimatoprost, travoprost and latanoprost.

Table 55.5 Side effects of prostanoids

Ocular Systemic
Asthenopia Abdominal cramp
Allergic conjunctivitis Asthenia
Blepharitis Asthma
Blepharospasm Bradycardia
Browache Dizziness
Cataract Dyspnoea
Conjunctival follicles, papillae Elevated liver function
Conjunctival hyperaemia Headache
Cystoid macular oedema Hirsutism
Corneal erosion Hypertension
Conjunctival oedema Hypotension
Deepening of lid sulcus Infection (primarily URTIs)
Distichiasis Peripheral oedema
Eye discharge Skin rash
Eye pain  
Eyelash changes – increased number, length, thickness, pigmentation, misdirection, poliosis  
Eyelid oedema, eyelid retraction  
Eyelid and periocular skin darkening  
Foreign body sensation  
Increase in vellus hair on eyelids  
Increased iris pigmentation  
Iritis  
Lid margin crusting  
Localised skin reactions on the eyelids  
Ocular burning, dryness, irritation pruritus, fatigue  
Photophobia  
Punctate epithelial erosions  
Retinal haemorrhage  
Tearing  
Uveitis  
Visual disturbance  

URTIs, upper respiratory tract infection

Latanoprost

Latanoprost, which is converted to its active free acid on entering the eye, was the first of the prostanoids to be launched and is the market leader. Like timolol amongst the β-blockers, latanoprost is the drug in this class against which new drugs or combinations are assessed. It must be administered in the evening for maximum effect (Stewart et al., 2008). Latanoprost is generally very well tolerated. Serious adverse drug reactions were reported in only 17/3936 (0.43%) patients using latanoprost over a 5-year period (Goldberg et al., 2008), and patient persistence with latanoprost therapy is better than that with all other frequently used monotherapies (Rahman et al., 2009). Latanoprost is not heat stable and requires refrigeration; however, it is stable enough to be stored at room temperature for the 4-week in-use period applied in the UK. The concentration of the preservative benzalkonium chloride in latanoprost eye drops and bimatoprost 0.01% may prevent their use in certain patients. The benzalkonium chloride concentration in these formulations is 0.02%, which is four times that in bimatoprost 0.03% eye drops. The current formulation of travoprost, launched in January 2011, contains polyquaternium-1 rather than benzalkonium chloride.

Bimatoprost

Bimatoprost is a fatty acid amide, pharmacologically similar to prostaglandin F1-ethanolamide (prostamide F).

Several mechanisms of action have been proposed including activity of bimatoprost or its free acid, 17-phenyl PGF2a, at the prostaglandin F receptor, prostamide mimetic activity, and inhibition of PGF synthase which leads to an increase in endogenous PGF. Although the free acid has been found in human eyes, its presence alone does not explain the 24-h efficacy of bimatoprost or its hypotensive superiority over latanoprost. The pharmacology of bimatoprost itself is not explained wholely by its interaction with known prostaglandin F receptors. It is administered once daily in the evening; more frequent administration may lessen the IOP-lowering effect.

Bimatoprost lowers the IOP to a greater extent than any other topical ocular hypotensive (van der Valk et al., 2009), an effect (see Table 55.2) which is sustained for at least 4 years (Williams et al., 2008). It is superior to latanoprost in terms of response rate, fall in IOP and the percentage of patients reaching their target IOP. In some studies, bimatoprost is reported to be as effective as the fixed combination of latanoprost and timolol. Many patients are non-responsive to latanoprost as they do not achieve a fall in IOP greater than 10%, although a large proportion of patients show a 20% or more fall in IOP with bimatoprost. Patients not reaching their target on latanoprost achieved lower IOPs when switched to bimatoprost (Sonty et al., 2008). Such patients achieve better diurnal control with bimatoprost than with a fixed combination of dorzolamide and timolol (Sharpe et al., 2008).

Generally, bimatoprost causes similar ocular side effects to latanoprost and travoprost, but while all the ocular prostanoids cause subclinical ocular inflammation, bimatoprost and travoprost cause this to a lesser degree than latanoprost. However, bimatoprost causes hyperaemia more frequently than latanoprost, although this is described as mild. This may contribute to the higher discontinuation rate seen with bimatoprost therapy (Rahman et al., 2009). To address this issue, the manufacturers of bimatoprost have introduced a lower strength (0.01%) version containing a higher concentration of benzalkonium chloride to aid penetration of the drug. In a 12-month study, the bimatoprost 0.01% was equivalent to bimatoprost 0.03% in lowering IOP and demonstrated improved tolerability, including less frequent and severe conjunctival hyperemia (Katz et al., 2010).

β-Adrenoceptor antagonists

The exact mechanism of action of β-adrenoceptor antagonists (β-blockers) in lowering IOP has not been fully established but is thought to result from the blockade of ciliary β-receptors, preventing the cyclic AMP-induced rise in aqueous secretion, as they have been shown to reduce aqueous humour formation rather than increase outflow. Although there are both β1– and β2-receptors in the eye, the latter predominate and even cardioselective β-blockers are thought to work by blockade of β2-receptors. Genetic factors have been shown to be important in patients’ response to this group of drugs (Nieminen et al., 2007, Sidjanin et al., 2008).

Four drugs are available in the UK for topical administration: betaxolol, carteolol, levobunolol and timolol (Table 55.6). β-Blockers have a number of important properties in addition to β-adrenoceptor blockade. These include intrinsic sympathomimetic activity (ISA), cardioselectivity and membrane-stabilising activity, which are all of importance when considering the side effects seen with these agents (Table 55.7). The property of membrane stabilisation is relevant to the incidence of ocular side effects. The absence of anaesthetic properties reduces the number and severity of foreign body and dryness sensations, anaesthesia of the cornea and dry eye syndrome.

Ocular side effects of topically administered β-blockers are shown in Table 55.8.

Table 55.8 Ocular and systemic side effects of topical β-blockers

Ocular Systemic
Allergic blepharoconjunctivitis Central nervous system
Burning and itching Anxiety
Blurred vision Depression
Conjunctival hyperaemia Fatigue
Corneal anaesthesia Hallucinations
Dryness Irritability
Foreign body sensation Sleep disturbances
Macular oedema Endocrine
Nasolacrimal duct obstruction Hypoglycaemia (insulin induced)
Pain Gastro-intestinal
Punctate keratitis Nausea
Uveitis Diarrhoea
Vascular
Arrhythmias
Bradycardia
Hypotension
Peripheral vasoconstriction
Reduced stroke volume
Respiratory
Bronchoconstriction
Dyspnoea

It has been suggested that those β-blockers that show ISA are less likely to produce bronchospasm and peripheral vascular side effects. Carteolol is the only commercially available drug that shows ISA. The selectivity of cardioselective β-blockers diminishes with increasing dosage, even within the therapeutic range. Betaxolol is the only commercially available topical β-blocker that demonstrates cardioselectivity.

A degree of bradycardia is commonly seen with all β-blockers, and β-blocker eye drops have been identified as the cause of episodes of orthostatic hypotension and syncope in elderly patients (Müller et al., 2006). The use of topical β-blockers in patients on verapamil, diltiazem, disopyramide, quinidine or amiodarone could potentiate bradycardia and should be avoided. Topical β-blockers are generally avoided in patients with normal-tension glaucoma because the nocturnal fall in arterial pressure causes a potentially dangerous reduction in ocular perfusion.

The precipitation of bronchospasm in susceptible patients can occur with the administration of as little as one drop of timolol. Those β-blockers that show cardioselectivity or ISA are less likely to cause bronchoconstriction, and it has been demonstrated that respiratory function improved in patients whose treatment was changed from timolol to betaxolol or an adrenergic agonist, these same patients having previously been asymptomatic.

All topical β-blockers have been reported to cause bronchospasm; hence, ‘at-risk’ patients with a tendency to airway disease who require therapy for glaucoma should be treated with extreme caution. Prescribers are advised that β-blockers, even those with apparent cardioselectivity, should not be used in patients with asthma or a history of obstructive airways disease unless no alternative treatment is available. In such cases, the risk of inducing bronchospasm should be appreciated and appropriate precautions taken. Lacrimal occlusion with intracanalicular plugs has been shown to almost completely prevent the bronchoconstriction caused by topical timolol in asthmatics by inhibiting or decreasing systemic absorption of the medication.

Ocular β-blockers are generally not contraindicated in diabetes, although a cardioselective agent may be preferable. However, they are best avoided in patients who suffer frequent hypoglycaemic attacks as they may mask the signs and symptoms of acute hypoglycaemia.

Systemic side effects of topically administered β-blockers are shown in Table 55.8.

The long-term benefits of β-blockers on visual function preservation have been shown to be less than would be expected. This may be due to adverse effects on the ocular microcirculation whereby the β-blockers interfere with endogenous vasodilation and cause optic nerve head arteriolar vasoconstriction. The various β-blockers demonstrate marked differences in their vasoconstrictive effect, with betaxolol possibly demonstrating the least vasoconstriction.

Betaxolol

In theory, because of its cardioselectivity, betaxolol should have fewer adverse effects on the pulmonary system. It should also have fewer adverse cardiovascular effects because of comparatively lower systemic β-receptor occupancy after ocular administration. Maximum occupancies for β1 and β2 receptors after ophthalmic administration were 52% and 88% for carteolol, 62% and 82% for timolol, and 44% and 3% for betaxolol, respectively. The lack of systemic effects of betaxolol compared with timolol has been highlighted by Easton who reported the case of an 85-year-old lady who developed atrial fibrillation on having her β-blocker eye drops changed from timolol to betaxolol (Easton, 2007)

However, betaxolol is less effective than other β-blockers as an ocular hypotensive agent (van der Valk, 2009). On initiation of treatment, the fall in IOP is slower than with other topical β-blockers. The 0.25% suspension is as effective as the 0.5% solution and is better tolerated by the patient (Yalvac et al., 2007). Experimental studies showed the drug reaches the retina after topical administration and displays a voltage-dependent L-type calcium channel-blocking activity, which probably leads to improved retinal perfusion. This effect may explain the significant improvement in visual field performance seen with betaxolol in a comparison study with timolol in open-angle glaucoma. The significant improvement with betaxolol occurred despite the more effective reductions in IOP with timolol.

Levobunolol

Levobunolol is the potent l-isomer of bunolol. It is metabolised to dihydrolevobunolol in the eye, prolonging the drug’s half-life and making it one of only two topical β-blockers licensed for once-daily use. It is as effective with once-daily dosing as the usual twice-daily regimen. It is not cardioselective, showing greater affinity for the β2-receptor, and does not possess ISA. It is reported to be as effective as timolol 0.5% and metipranolol 0.6% (now discontinued) in lowering IOP and more effective than betaxolol 0.5%. The incidence of allergic contact dermatitis is greater with levobunolol than timolol (Jappe et al., 2006), and a greater percentage of patients on levobunolol than timolol or betaxolol discontinued the drug due to adverse effects (Rahman et al., 2009). Its effect on tear volume and corneal epithelial barrier function is similar to that produced by timolol, and it has less effect on non-invasive break-up time of the precorneal tear film. This may be attributable to its formulation which includes polyvinyl alcohol. Levobunolol appears to have no effect on the retinal and choroidal vasculature.

Timolol

This non-cardioselective β-blocker without ISA was the first to be introduced, and as such is the agent against which all newer β-blockers were compared. It is effective in the long-term treatment of glaucoma, often in conjunction with other antiglaucoma therapy in terms of IOP lowering. Many patients can be placed on once-a-day therapy provided the IOP is maintained at satisfactory levels. However, the presentation of timolol in a prolonged-release formulation (a polysaccharide-based, gel-forming solution) leads to a prolonged corneal contact time and increased penetration of timolol into the eye. This is the preferred form for once-daily administration. Both timolol eye gels, 0.1% and 0.5%, have been shown to be as effective as the 0.5% solution administered twice daily. The 0.1% gel has the advantage of a much lower drug load, giving rise to plasma levels of timolol 10 times lower than achieved after twice-daily dosage of timolol 0.5% eye drops. The concentration of timolol achieved in the aqueous humour following administration of the 0.1% gel formulation, despite being approximately 40% of that following administration of the 0.5% solution is sufficient to occupy 100% of β1– and β2-receptors (Volotinen et al., 2009). Timolol is available in combination products with the carbonic anhydrase inhibitors brinzolamide and dorzolamide, the prostaglandin analogues latanoprost and travaprost, the prostamide bimatoprost and the sympathomimetic brimonidine (see Table 55.6).

Sympathomimetic agents

The original sympathomimetic drug used in the treatment of OHT and open-angle glaucoma, adrenaline (epinephrine) and its lipophilic pro-drug dipivefrine have been discontinued. Adrenaline (epinephrine) is an α- and β-adrenoreceptor agonist. It decreases IOP by reducing aqueous inflow via an α-mediated vasoconstriction in the ciliary body and increased outflow due to a dilation of the aqueous and episcleral veins. Adrenaline (epinephrine) is a mydriatic and therefore its use is contraindicated in PACG and in patients who show a shallow anterior chamber, because of the risk of precipitating angle closure. More selective sympathomimetics apraclonidine and brimonidine are in use today.

Brimonidine

More α2-selectivity is seen with brimonidine, which results in miosis rather than mydriasis. Vasoconstriction of microvessels is also not seen. It is thought to increase uveoscleral outflow as well as reducing aqueous production. Brimonidine administered twice daily is almost as effective as timolol twice a day at peak. However, bromonidine is significantly less effective at trough, and some consider it to be more efficacious when administered three times a day, the frequency used in the USA. Brimonidine may be used as monotherapy to lower IOP in patients with open-angle glaucoma or OHT who are intolerant of β-blockers or in whom β-blockers are contraindicated, as there is no effect on pulmonary function and only minimal cardiovascular effect. It may also be used as an adjunctive therapy in those patients whose IOP is not adequately controlled with a single agent as its IOP-lowering activity has been shown to be additive to that of β-blockers and prostaglandin analogues.

A database containing details of drug use in 956 glaucoma patients over 18 years shows that brimonidine had the highest proportion of discontinuations due to adverse effects (Rahman et al., 2009). It has high allergenicity and may increase the likelihood of allergy to preparations subsequently used.

A formulation of brimonidine, brimonidine-Purite 0.15%, given twice daily, has been shown to be as effective as brimonidine 0.2% twice a day. It has a more favourable safety and tolerability profile, a reduced incidence of allergic conjunctivitis and better patient satisfaction and comfort rating. In a 4-month study, co-administration of latanoprost and brimonidine 0.15% results in a greater fall in IOP than co-administration of latanoprost and brinzolamide or dorzolamide (Bournias and Lai, 2009). This product is not available in the UK.

Brimonidine is contraindicated in patients receiving monoamine oxidase inhibitors or antidepressants which affect noradrenergic transmission, and there is the possibility of brimonidine potentiating or causing an additive effect with CNS depressants. Its use is contraindicated in children in whom it causes drowsiness, ataxia, pallor, irritability, hypotension, bradycardia, miosis and respiratory depression (Lai Becker et al., 2009).

Experimental evidence in animals has demonstrated that brimonidine is a potential neuroprotective agent. However, to date, clinical trials have failed to translate into similar efficacy in humans (Saylor et al., 2009).

Commercially available preparations of sympathomimetic agents are shown in Table 55.10.

Miotics

Miotics act to increase the outflow of aqueous humour by a stimulation of ciliary muscle and an opening of channels in the trabecular meshwork. Miotics are directly acting parasympathomimetic agents that act at muscarinic receptors. The only such drug currently available commercially in the UK is pilocarpine.

Miosis is an unwanted incidental effect and can cause considerable difficulties to patients. Reduced visual acuity, especially in the presence of central lens opacities, spasm of accommodation, accompanied by severe frontal headache (browache) and diminished night vision may cause poor adherence in many patients.

Ocular side effects of pilocarpine are shown in Box 55.1. In eyes with narrow angles, PACG may be precipitated by an aggravation of pupillary block. Systemic side effects are due to parasympathetic stimulation and include anxiety, bradycardia, diarrhoea, nausea, vomiting and sweating (Box 55.2).

The onset of action of pilocarpine is 20 min, but its short duration of action necessitates four times daily dosing. The frequency of instillation of pilocarpine eye drops is a major disadvantage, and advances have been made to reduce the inconvenience of a four-times-daily dosage regimen. A slow-release gel preparation, Pilogel (Table 55.11), has been introduced. A single daily application, administered at bedtime, allows low IOP to be maintained for 24 h, with the patient sleeping through the more troublesome ocular side effects.

Carbonic anhydrase inhibitors

There are many forms of the enzyme carbonic anhydrase, three of which (CA-I, CA-II and CA-IV) are present in ocular tissues. In the ciliary epithelium, the inhibition of CA-II slows the formation of bicarbonate ions and their secretion into the posterior chamber of the eye. This reduces the sodium transport into the posterior chamber and decreases aqueous humour production, resulting in lower IOP. Inhibition of other forms of the enzyme results in many side effects.

Topical carbonic anhydrase inhibitors

The topical carbonic anhydrase inhibitors dorzolamide and brinzolamide are useful alternatives to acetazolamide in glaucoma management. They are licensed as monotherapy for patients with OHT or open-angle glaucoma resistant to β-blockers or those in whom use of β-blockers is contra-indicated. Dorzolamide is also licensed for the treatment of pseudo-exfoliative glaucoma, and limited clinical data in paediatric patients are available. Both drugs are licensed as adjunctive therapy to β-blockers and brinzolamide to prostaglandin analogues, although there is evidence to suggest that dorzolamide is as efficacious as brinzolamide when added to latanoprost (Nakamura et al., 2009).

Dorzolamide is used either alone three times a day or concurrently with a β-blocker or twice daily with a prostaglandin analogue. While the licence for brinzolamide states that the drug can be used twice a day as monotherapy, some patients may respond better to a three times daily dosage. Mean changes in IOP with brinzolamide administered twice daily and three times daily and dorzolamide administered three times daily are equivalent. However, the fall in IOP achieved with these agents is less than that seen with timolol 0.5% twice daily.

Side effects similar to those of systemic sulphonamides may occur and should be watched for. The most common side effects are shown in Table 55.12. Of the two topical carbonic anhydrase inhibitors, brinzolamide appears to cause less burning and stinging on instillation due to the neutral pH (7.5) of the formulation. This is reflected in a much greater discontinuation rate with dorzolamide (31%) than with brinzolamide (14%) (Rahman et al., 2009).

Table 55.12 Side effects of topical carbonic anhydrase inhibitors

Ocular Systemic
Blurred vision Dry mouth
Burning/stinging Dyspnoea
Conjunctivitis Headache
Eyelid pain/discomfort Nausea
Fatigue Taste perversion
Itching  
Nasolacrimal duct obstruction  
Ocular discharge  
Tearing  

Animal studies suggested that both topical carbonic anhydrase inhibitors may improve ocular blood flow independent of the IOP; however, while this has been well established for dorzolamide in humans, data for brinzolamide are limited. It remains to be established whether this effect can help reduce visual field loss in patients with glaucoma.

Combination products

A large number of patients require more than one medication to achieve target pressure. A need for the patient to use two products concomitantly may lead to confusion, with multiple instillation of one product and non-use of the other. Also, if the second drop is instilled too soon after the first, wash-out of the first product with the second drop, overflow of the precorneal tear film and a dilution of both products may occur. In addition, the patient receives a larger dose of preservative which can irritate the eye and is a common reason for non-tolerance of the regimen. The combination of two drugs in one topical ophthalmic preparation may improve adherence and result in a reduction in preservative load. Single rather than multi-drop combinations are recommended to improve adherence and maintain patients’ quality of life.

For a combination of two drugs to be an acceptable alternative to the prescriber, the fixed combination must be more effective than either of the components used alone and at least as effective as the drugs administered separately, that is not demonstrate antagonism. In addition, adverse effects of the fixed combination must not be more numerous or more frequently encountered than with the components administered separately. There are six products in which timolol is combined with a second ocular hypotensive agent. They differ slightly in their therapeutic indications.

Fixed combination of timolol and travoprost

A fixed combination of travoprost 0.004% and timolol 0.5% (DuoTrav®) has been shown to be more effective than either of its components and is as efficacious as the components administered concomitantly while fewer side effects are reported with the combination product (Gross et al., 2007). The fixed combination of travoprost and timolol is indicated to decrease IOP in patients with open-angle glaucoma or OHT who are insufficiently responsive to topical β-blockers or prostaglandin analogues. Although the Summary of Product Characteristics states that the dose is one drop in the affected eye(s) once daily, in the morning or evening, it has been shown that an evening dose demonstrates better 24-h pressure control (Konstas et al., 2009).

Hyperosmotic agents

Hyperosmotic agents are of great value during PACG emergencies due to their speed of action and effectiveness. The most commonly used agents are oral glycerol and intravenous mannitol, although both isosorbide and urea have been used in the past. Hyperosmotic agents act by drawing water out of the eye and therefore lower IOP. The maximal effect of glycerol is seen within 1 h and lasts for about 3 h, while mannitol acts within 30 min with effects lasting for 4–6 h.

Patient care

Chronic open-angle glaucoma

When the condition is first diagnosed, patients should be told that the disorder cannot be cured but only controlled by the regular use of the prescribed treatment. As patients may not be aware of progression of the disease, the result of non-adherence with treatment should be made clear and the importance of regular attendance at clinics stressed.

The existence of a patient self-help group, the International Glaucoma Association (http://www.glaucoma-association.com), should be brought to the patient’s attention. They will be able to put the patient in contact with their nearest support group.

The patient’s technique for instillation of eye drops should be checked and corrected if necessary. Emphasis should be on the dose (one drop), the position of instillation, into the temporal side of the lower conjunctival sac, and the importance of punctal occlusion to minimise systemic side effects.

The preferred times for administration of topical medication should be discussed with the patient. Prostaglandins, prostamides and the gel form of pilocarpine are best administered at bedtime; a 12-hourly regimen should be employed for twice-daily drugs; 8-hourly for drugs given three times a day; and as near a 6-hourly regimen as practical for the aqueous formulation of pilocarpine. β-Blockers given once daily should be administered in the morning. The importance of allowing a reasonable interval between drops should be emphasised. Sometimes, the order of instillation of different types of eye drop is important for pharmacological or practical reasons. For example, the instillation of pilocarpine should always precede that of a sympathomimetic to prevent pain in the eye resulting from a strong miosis following a weak mydriasis. The instillation of aqueous eye drops, which remain in the conjunctival sac for a maximum of 10 min, should precede that of viscous eye drops, for example hypromellose eye drops, or suspensions (e.g. dexamethasone 0.1% eye drops) where the contact time is prolonged.

Eye drops containing benzalkonium chloride should not be instilled if soft contact lenses are in situ. The patient should be instructed to remove the lens immediately before instillation and replace it approximately 30 min later.

As there is a hereditary component to COAG, patients should be told to advise first-degree relatives to be screened. Such people over the age of 40 years are entitled to free eye tests by their optometrist.

Primary angle-closure glaucoma

Patients found to have shallow anterior chambers and narrow angles are normally promptly listed for peripheral iridectomies. However, if the procedure is delayed, they should be advised of the symptoms of an attack of acute PACG and details of the factors that are likely to precipitate an attack so that they can be avoided. They should be advised that there are a number of prescription and non-prescription drugs that they should not take (Lachkar and Bouassida, 2007). When visiting the doctor and purchasing medicines from a pharmacy, the patient should always remember to mention their condition, and the prescriber should ensure that the drug is appropriate for a patient prone to angle closure. Examples of drugs contraindicated in this condition are listed in Table 55.14. Note that the absence of a drug from this list does not imply safety.

Table 55.14 Drugs contraindicated in narrow-angle glaucoma

Therapeutic class   Examples
Antimuscarinics Topical Atropine, cyclopentolate, homatropine, tropicamide
Antispasmodic Atropine, dicycloverine, hyoscine, propantheline
Motion sickness Hyoscine, promethazine, cyclizine
Bronchodilator Ipratropium, tiotropium
Urinary retention Darifenacin, fesoterodine, flavoxate, oxybutynin, propiverine, solifenacin, tolterodine, trospium
Drugs used in anaesthesia   Glycopyrronium, ketamine, suxamethonium
Antidepressants   Amitriptyline, amoxapine, citalopram, clomipramine, dosulepin, doxepin,duloxetine,fluvoxamine, imipramine, lofepramine, maprotiline, mirtazapine, nortriptyline, paroxetine, phernelzine, reboxetine, sertraline, trazodone, trimipramine, venlafaxine
Antipsychotics   Chlorpromazine, clozapine, flupentixol, fluphenazine, olanzapine, pericyazine, perphenazine, pipotiazine, promazine, risperidone, sulpiride, thioridazine, trifluoperazine, zuclopentixol
Antihistamines   Alimemazine, antazoline, cetirizine, chlorphenamine, clemastine, cyproheptadine, diphenhydramine, hydroxyzine, loratidine, pizotifen
Antiarrhythmics   Disopyramide
Antiepileptics   Carbamazepine, topiramate
Sympathomimetics   Adrenaline, cocaine, dipivefrine, ephedrine, isometheptene, naphazoline, phenylephrine, pseudoephedrine, salbutamol, xylometazoline
Drugs used in the treatment of ADHD   Atomoxetine, dexamfetamine, methylphenidate, ritodrine
Drugs used in the treatment of parkinsonism   Benserazide, carbidopa, entacapone, levodopa, orphenadrine, procyclidine, selegiline, trihexyphenidyl,
Non-steroidal anti-inflammatory drugs   Mefenamic acid
Sulphonamide derived drugs   Acetazolamide, co-trimoxazole, hydrochlorothiazide, sulphasalazine
Miscellaneous   Botulinum toxin, carboprost, paracalcitol, pilocarpine

Following an attack of angle closure and surgical treatment of the disorder, the patient should be told that the drugs previously contraindicated can be safely taken provided that iridectomy/iridotomy remains patent.

Patient adherence

The patient is more likely to comply with the prescribed treatment if the drug or drugs can be administered according to a simple, infrequent dosage regimen and cause no or few, local or systemic side effects.

Thus, a patient treated with a once-daily prostaglandin analogue or prostamide or once- or twice-daily β-blocker would be expected to adhere to the regimen better than someone treated with pilocarpine, with its unfortunate side effects and inconvenient four-times-a-day dosage regimen. Common side effects of topical and systemic medication should be fully discussed with the patient so that the hyperaemia encountered with the prostanoids and the paraesthesia with acetazolamide are not unexpected, leading to premature discontinuation of therapy.

As glaucoma is predominantly a disease of elderly people, physical disability may prevent successful treatment, however conscientious the patient. For example, rheumatoid arthritis may reduce the patient’s ability to squeeze the bottle of eye drops, while the tremor of Parkinson’s disease can make correct positioning of instillation difficult. Various aids have been introduced to help with correct positioning and squeezing of eye drops, and these should be made available to patients so disabled.

Patients with poor visual acuity can be helped by colour coding of eye drop labels and supplying bottles labelled with large print. Some manufacturers have endeavoured to enhance adherence by including dose-reminder caps and facilitating instillation by supplying aids to open or position the bottle. Other manufacturers have made their eye drop containers easier to squeeze or supply aids to squeeze the bottle. A list of such devices, some of which are available on prescription, others free of charge from manufacturers of drugs used in the treatment of glaucoma is available on the International Glaucoma Association’s website (http://www.glaucoma-association.com/).

Where self-medication is impossible, a simple infrequent dosage regimen is more likely to be achieved when a relative, a neighbour or the district nursing service becomes responsible for administration of the medication. In these cases, a drug administered once daily, such as a long-acting timolol preparation or a prostaglandin analogue or bimatoprost, has an obvious advantage over one that should be administered at 12-hourly intervals. If pilocarpine is required and bedtime administration is possible, the prescribing of pilocarpine ophthalmic gel will be more practical than pilocarpine eye drops, the administration of which is totally impractical for anyone other than someone living with the patient.

Common therapeutic problems in glaucoma are listed in Table 55.15.

Table 55.15 Common therapeutic problems in glaucoma

Problem Comments
Lack of adherence Treatment perceived to be worse than disease
Complex multiple drug regimens
Frequency of dosing
Inability to differentiate between different types of medication
Inability to instil medication
Contraindication to therapy Pilocarpine in uveitis
β-Blockers in asthma, bradycardia, heart block, uncontrolled heart failure
Prostaglandin analogues and prostamides in aphakia
Wide range of topical and systemic drugs in shallow anterior chamber
α2-agonists in depression
Carbonic anhydrase inhibitors in renal failure
Intolerance to drug Miosis and ciliary spasm with pilocarpine
Red eye with prostaglandin analogues, bimatoprost
Bronchospasm with β-blockers
Paraesthesia with acetazolamide
Use outside licensed indications Paediatric patients
Pregnant women
Nursing mothers
Hypersensitivity To active drug
To preservative in multidose formulations

Case studies

References

Bournias T.E., Lai J. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs. Ophthalmology. 2009;116:1719-1724.

Brandt J.D., Cantor L.B., Katz L.J., et al. Ganfort Investigators Group II 2008 Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J. Glaucoma.. 2008;17:211-216.

Easton P.J. A cardiovascular benefit of ophthalmic beta-blockade. Age and Ageing.. 2007;36:351.

Egorov E., Ropo A. Adjunctive use of tafluprost with timolol provides additive effects for reduction of intraocular pressure in patients with glaucoma. Eur. J. Ophthalmol.. 2009;19:214-222.

European Glaucoma Society. Terminology and Guidelines for Glaucoma, third ed. Savona: Editrice Dogma; 2008. Available at http://www.eugs.org/eng/EGS_guidelines.asp

Eyawo O., Nachega J., Lefebvre P., et al. Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis. Clin. Ophthalmol.. 2009;3:447-456.

Goldberg I., Li X.Y., Selaru P., et al. A 5-year, randomized, open-label safety study of latanoprost and usual care in patients with open-angle glaucoma or ocular hypertension. Eur. J. Ophthalmol.. 2008;18:408-416.

Gross R.L., Sullivan E.K., Wells D.T., et al. Pooled results of two randomized clinical trials comparing the efficacy and safety of travoprost 0.004%/timolol 0.5% in fixed combination versus concomitant travoprost 0.004% and timolol 0.5%. Clin. Ophthalmol.. 2007;1:317-322.

Hamacher T., Airaksinen J., Saarela V., et al. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. Acta Ophthalmol. (Copenh). 2008;86(S242):14-19.

Honrubia F., García-Sánchez J., Polo V., et al. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. Br. J. Ophthalmol.. 2009;93:316-321.

Jappe U., Uter W., Menezes de Pádua C.A., et al. Allergic contact dermatitis due to beta-blockers in eye drops: a retrospective analysis of multicentre surveillance data 1993–2004. Acta Derm. Venereol.. 2006;86:509-514.

Johnson T.V., Toris C.B., Fan S. Effects of central corneal thickness on the efficacy of topical ocular hypotensive medications. J. Glaucoma.. 2008;17:89-99.

Kaback M., Scoper S.V., Arzeno G., et al. Brinzolamide 1%/timolol 0.5% Study Group. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%. Ophthalmology. 2008;115:1728-1734.

Katz L.J., Cohen J.S., Batoosingh A.L., et al. Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. Am. J. Ophthalmol.. 2010;149:661-671.

Kenigsberg P.A. Changes in medical and surgical treatments of glaucoma between 1997 and 2003 in France. Eur. J. Ophthalmol.. 2007;17:521-527.

Konstas A.G., Tsironi S., Vakalis A.N., et al. Intraocular pressure control over 24 hours using travoprost and timolol fixed combination administered in the morning or evening in primary open-angle and exfoliative glaucoma. Acta Ophthalmol. (Copenh). 2009;87:71-76.

Lachkar Y., Bouassida W. Drug-induced acute angle closure glaucoma. Curr. Opin. Ophthalmol.. 2007;18:129-133.

Lai Becker M., Huntington N., Woolf A.D. Brimonidine tartrate poisoning in children: frequency, trends, and use of naloxone as an antidote. Pediatrics. 2009;123:e305-e311. Available at http://pediatrics.aappublications.org/cgi/reprint/123/2/e305.pdf

Lim K.S., Nau C.B., O’Byrne M.M., et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008;115:790-795.

Manni G., Denis P., Chew P., et al. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J. Glaucoma.. 2009;18:293-300.

Motolko M.A. Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapy. Curr. Med. Res. Opin.. 2008;24:2663-2667.

Müller M.E., van der Velde N., Krulder J.W., et al. Syncope and falls due to timolol eye drops. Br. Med. J.. 2006;332:960-961.

Mundorf T.K., Rauchman S.H., Williams R.D., et al. Brinzolamide/Timolol Preference Study Group. A patient preference comparison of Azarga (brinzolamide/timolol fixed combination) vs Cosopt (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension. Clin. Ophthalmol.. 2008;2:623-628.

Nakamura Y., Ishikawa S., Nakamura Y., et al. 24-hour intraocular pressure in glaucoma patients randomized to receive dorzolamide or brinzolamide in combination with latanoprost. Clin. Ophthalmol.. 2009;3:395-400.

National Institute for Health and Clinical Excellence. Glaucoma: Diagnosis and Management of Chronic Open Angle Glaucoma and Ocular Hypertension. London: NICE; 2009. Available at http://guidance.nice.org.uk/CG85

Nieminen T., Lehtimäki T., Mäenpää J., et al. Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects. Scand. J. Clin. Lab. Invest.. 2007;67:237-245.

Papaconstantinou D., Georgalas I., Kourtis N., et al. Preliminary results following the use of a fixed combination of timolol-brimonidine in patients with ocular hypertension and primary open-angle glaucoma. Clin. Ophthalmol.. 2009;3:227-230.

Rahman M.Q., Montgomery D.M., Lazaridou M.N. Surveillance of glaucoma medical therapy in a Glasgow teaching hospital: 26 years’ experience. Br. J. Ophthalmol.. 2009;93:1572-1575.

Rolim de Moura C., Paranhos JrA, Wormald R. Laser trabeculoplasty for open angle glaucoma. Cochrane Database Syst. Rev.. (4.):2007. Art. No.: CD003919. DOI: 10.1002/14651858.CD003919.pub2

Saylor M., McLoon L.K., Harrison A.R., et al. Experimental and clinical evidence for Brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review. Arch. Ophthal.. 2009;127:402-406.

Sharpe E.D., Williams R.D., Stewart R.D., et al. A comparison of dorzolamide/timolol-fixed combination versus bimatoprost in patients with open-angle glaucoma who are poorly controlled on latanoprost. J. Ocul. Pharmacol. Therapeut.. 2008;24:408-413.

Sherwood M.B., Craven E.R., Chou C., et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch. Ophthal.. 2006;124:1230-1238.

Sidjanin D.J., McCarty C.A., Patchett R., et al. Pharmacogenetics of ophthalmic topical beta-blockers. Personal. Med.. 2008;5:377-385.

Sonty S., Donthamsetti V., Vangipuram G., et al. Long-term IOP lowering with bimatoprost in open-angle glaucoma patients poorly responsive to latanoprost. J. Ocul. Pharmacol. Therapeut.. 2008;24:517-520.

Stewart W.C., Konstas A.G., Nelson L.A., et al. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology. 2008;115:1117-1122.

Takmaz T., Aşik S., Kürkçüolu P., et al. Comparison of intraocular pressure lowering effect of once daily morning vs evening dosing of latanoprost/timolol maleate combination. Eur. J. Ophthalmol.. 2008;18:60-65.

Toris C.B., Gabelt B.T., Kaufman P.L. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv. Ophthalmol.. 2008;53(Suppl. 1):S107-S120.

van der Valk R., Webers C.A., Lumley T., et al. A network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressure. J. Clin. Epidemiol.. 2009;62:1279-1283.

Volotinen M., Mäenpää J., Kautiainen H., et al. Ophthalmic timolol in a hydrogel vehicle leads to minor inter-individual variation in timolol concentration in aqueous humor. Eur. J. Pharmaceuti. Sci.. 2009;36:292-296.

Williams R.D., Cohen J.S., Gross R.L., et al. Bimatoprost Study Group. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4. Br. J. Ophthalmol.. 2008;92:1387-1392.

Wright T.M., Freedman S.F. Exposure to topical apraclonidine in children with glaucoma. J. Glaucoma.. 2009;18:395-398.

Yalvac I.S., Basci N.E., Dulger B., et al. Penetration of betaxolol HCL ionic suspension 0.25% and betaxolol HCL solution 0.50% into the aqueous humor. Eur. J. Ophthalmol.. 2007;17:368-371.

Yeh J., Kravitz D., Francis B. Rational use of the fixed combination of dorzolamide – timolol in the management of raised intraocular pressure and glaucoma. Clin. Ophthalmol.. 2008;2:389-399.